A Randomized, Double-Blind, Double Dummy, Multicenter Phase II/III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated with Chemotherapy
An open-lable, single-center, phase I/IIA study to assess safety, tolerance, pharmacokinetics and efficacy of oral dosing icotinib hydrochloride tablets in various cancer patients,mainly in NSCLC
A phase I study to assess safety, tolerance and pharmacokinetics of oral dosing Icotinib Hydrochloride Tablets
100 Clinical Results associated with Zhejiang Betta Pharmaceuticals Co., Ltd.
0 Patents (Medical) associated with Zhejiang Betta Pharmaceuticals Co., Ltd.
01 Nov 2018·ANNALS OF ONCOLOGY
Efficacy of icotinib in advanced lung squamous cell carcinoma
Article
Author: Liang, S ; Xu, Y ; Ma, Y ; Tan, F ; Ding, L ; Wang, M
100 Deals associated with Zhejiang Betta Pharmaceuticals Co., Ltd.
100 Translational Medicine associated with Zhejiang Betta Pharmaceuticals Co., Ltd.